Holen Sie sich die Stockscreener-App
19.19
0.10%
-0.02
Handel nachbörslich:
19.19
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference - Yahoo Finance
Bicara Therapeutics stock hits 52-week high at 19.72 USD By Investing.com - Investing.com Nigeria
Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (BCAX) Is Up 11.9% After US$172.5 Million Equity Raise And CEO Share Sale - simplywall.st
United StatesGoodwin Advises Bicara Therapeutics On Closing Of $172.5 Million Oversubscribed Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Bicara Therapeutics Inc. targets fibrotic tumor barriers in HPV negative R M HNSCC - Traders Union
Bicara Therapeutics stock hits 52-week high at 19.72 USD - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After FICERA Data And Capital Raise - Sahm
Stock Report: Can Bicara Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - Naître et grandir
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Bicara Therapeuti - GuruFocus
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock - Investing.com UK
Aug Sectors: How is Bicara Therapeutics Inc managing supply chain issuesMarket Volume Report & High Conviction Investment Ideas - baoquankhu1.vn
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares - MarketBeat
Fundamentals Check: How cyclical is Bicara Therapeutics Incs revenue streamWeekly Risk Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference - Yahoo Finance
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 16,300 Shares of Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $54,074.75 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 17,392 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 13,555 Shares - MarketBeat
Cohlhepp, Bicara Therapeutics president, sells $315k in shares By Investing.com - Investing.com Australia
Cohlhepp, Bicara Therapeutics president, sells $315k in shares - Investing.com South Africa
Bicara Therapeutics Inc builds enduring patient trust - Traders Union
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Bitget
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
BCAX (Nasdaq) insider sale: 16,300 shares via option exercise (03/04/2026) - Stock Titan
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug - simplywall.st
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BCAX (NASDAQ) insider to sell 13,555 shares after option exercise - Stock Titan
Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX) - Stock Titan
BCAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Bicara Therapeutics Inc benefit from rate cuts2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Chart Watch: Is Bicara Therapeutics Incs growth already priced inWeekly Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Major Insider Move Signals Growing Confidence in Bicara Therapeutics - TipRanks
Bicara Therapeutics (BCAX) stake reaches 11.5% at RA Capital group - Stock Titan
RA Capital funds boost Bicara Therapeutics (BCAX) stake with stock and warrants - Stock Titan
Assessing Bicara Therapeutics (BCAX) Valuation After Recent Share Price Moves And DCF Implied Upside - simplywall.st
Bicara Therapeutics (BCAX) President/COO sells 3,631 shares after option exercise - Stock Titan
Bicara Therapeutics closes $172.5 million stock offering By Investing.com - Investing.com India
Bicara Therapeutics Inc. closes oversubscribed equity offering to fund ficerafusp alfa advancement - Traders Union
Bicara Therapeutics Strengthens Finances with Equity Offering - TipRanks
Bicara Therapeutics closes $172.5 million stock offering - Investing.com South Africa
Bicara Therapeutics (NASDAQ: BCAX) raises $161.8M to fund ficerafusp alfa - Stock Titan
Bicara Therapeutics Announces Closing of Oversubscribed - GlobeNewswire
Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX - Defense World
Bicara Therapeutics prices $150 million stock offering at $16 By Investing.com - Investing.com Australia
Ryan Cohlhepp sells BCAX shares (BCAX) in multiple transactions - Stock Titan
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:BCAX) 2026-02-25 - Seeking Alpha
Bicara Therapeutics Announces Public Offering Details - Intellectia AI
Biotech prices $150M deal to fund solid tumor drug plans in US - Stock Titan
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):